Skip to content

Newsroom

Welcome to Orion's newsroom where you can find the latest releases and articles.

Stock exchange releases

All releases 

Press releases

7/21/2025 Darolutamide receives EU approval in third indication for patients with advanced prostate cancer
7/4/2025 Orion publishes Half-Year Financial Report for January–June 2025 and holds a webcast on 18 July 2025
6/20/2025 CHMP recommends third indication for darolutamide for patients with advanced prostate cancer
6/17/2025 Orion and Glykos announce the extension of their research collaboration and licensing agreement for the development of next-generation ADCs

All releases 

Subscribe to releases

Subscribe Orion Corporation's stock exchange and press releases to your e-mail.

Subscribe

Content themes

Orion Pharma content bank

You can find and download Orion Pharma brand assets in the content bank.

Sign in or registrate

Corporate Communications

Terhi Ormio

Vice President, Communications; primary media contact

terhi.ormio@orion.fi

+358104264646
Tuukka Hirvonen

Head of Investor Relations

tuukka.hirvonen@orion.fi

+358104262721
Mari Lautsuo

Communications Manager

mari.lautsuo@orion.fi

+358104262156
Valtteri Manninen

Communications Manager

valtteri.manninen@orion.fi

+358104262303
Verna Vuorinen

Communications & Brand Manager

verna.vuorinen@orion.fi

+358104262211

Disclosure policy

In its communications, Orion Corporation complies with valid legislation, the rules and insider guidelines of Nasdaq Helsinki Ltd, the regulations and guidelines of the Financial Supervisory Authority and the instructions and principles defined internally in the company.